Home > Search Results

Results: 17

Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI

We reviewed the evidence about the effectiveness and safety of treating mucopolysaccharidosis type VI by enzyme replacement therapy with galsulfase (a manufactured version of the enzyme arylsulphatase B) compared to other interventions, no intervention or placebo.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Steroids for short‐term symptom control in infectious mononucleosis (glandular fever)

We reviewed evidence about the effect of steroids on symptom control in people with glandular fever (infectious mononucleosis) when compared to placebo or different medications.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Enzyme replacement therapy with laronidase as a treatment for mucopolysaccharidosis type I (MPS I)

We reviewed the evidence about the effect and safety of enzyme replacement therapy with laronidase for people with mucopolysaccharidosis type I who do not undergo haemopoietic stem cell transplantation. and in people with mucopolysaccharidosis I who receive enzyme replacement therapy prior to haemopoietic stem cell transplantation. This is an updated version of the original Cochrane review published in 2013.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2016

Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of myelodysplastic/myeloproliferative neoplasms including chronic/juvenile myelomonocytic leukemias and atypical CML.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 2, 2015

Suspected Cancer: Recognition and Referral

Cancer is an important condition, both in terms of the number of people affected and the impacts on those people and the people close to them. Around one third of a million new cancers are diagnosed annually in the UK, across over 200 different cancer types. Each of these cancer types has different presenting features, though there may be overlap. More than one third of the population will develop a cancer in their lifetime. Although there have been large advances in treatment and survival, with a half of cancer sufferers now living at least ten years after diagnosis, it remains the case that more than a quarter of all people alive now will die of cancer.

NICE Guideline - National Collaborating Centre for Cancer (UK).

Version: June 2015
Show search results within this document

AIDS-Related Lymphoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 2, 2015

Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of chronic myeloproliferative neoplasms.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 21, 2015

Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation

Chronic myeloid leukaemia (CML) is a form of cancer affecting the blood, characterised by excessive proliferation of white blood cells in the bone marrow and circulating blood. In the UK, an estimated 560 new cases of CML are diagnosed each year.

Health Technology Assessment - NIHR Journals Library.

Version: April 2012
Show search results within this document

Dasatinib, High-Dose Imatinib and Nilotinib for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation

The present report was commissioned as a supplement to an existing technology assessment report produced by the Peninsula Technology Assessment Group (PenTAG), which evaluated the clinical effectiveness and cost-effectiveness of dasatinib and nilotinib in patients who are either resistant or intolerant to standard-dose imatinib.

Health Technology Assessment - NIHR Journals Library.

Version: May 2012
Show search results within this document

Chronic Lymphocytic Leukemia Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: October 21, 2016

Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of myelodysplastic syndromes (MDS).

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: April 2, 2015

Langerhans Cell Histiocytosis Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood Langerhans Cell Histiocytosis.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: November 30, 2016

Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: December 1, 2016

Diarrhoea and Vomiting Caused by Gastroenteritis: Diagnosis, Assessment and Management in Children Younger than 5 Years

When young children suddenly experience the onset of diarrhoea, with or without vomiting, infective gastroenteritis is by far the most common explanation. A range of enteric viruses, bacteria and protozoal pathogens may be responsible. Viral infections account for most cases in the developed world. Gastroenteritis is very common, with many infants and young children experiencing more than one episode in a year.

NICE Clinical Guidelines - National Collaborating Centre for Women's and Children's Health (UK).

Version: April 2009
Show search results within this document

Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: November 30, 2016

Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: November 22, 2016

Donor Breast Milk Banks: The Operation of Donor Milk Bank Services

Seventeen donor breast milk banks are currently in operation in the UK. These provide donor milk to babies, including pre-term babies and babies with growth restriction.

NICE Clinical Guidelines - National Institute for Health and Clinical Excellence (UK).

Version: February 2010
Show search results within this document

Systematic Reviews in PubMed

See all (41)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...